Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

A powerful and efficient tissue regeneration method for reducing the anastomotic leakage rate in gastrointestinal surgery

Project description

Innovative technology addresses a severe GI surgery complication

Anastomotic leakage is a common severe complication after gastrointestinal (GI) surgery affecting morbidity and mortality. Danish company Vivostat has developed an autologous bioactive fibrin matrix for improved sealing and tissue healing which demonstrates a very low anastomotic leakage rate in a retrospective clinical observational trial. The EU-funded OBSIDIAN project is providing support for the final stage in the development of the product for anastomoses in colorectal surgery and preparing it for commercialisation, by securing funding for the large-scale EU-based randomised controlled clinical trial. The introduction of this new product is anticipated to save numerous lives and decrease the immense global healthcare costs associated with anastomotic leakages.

Objective

For more than 4 years, Vivostat® together with Rivolution® have been working to develop Obsidian ASG® with the aim to reduce anastomotic leakage in gastrointestinal (GI) surgery. Obsidian ASG® is a best-in-class autologous bioactive fibrin matrix with sustained release of active cells and growth factors providing improved sealing and healing. A preliminary retrospective, single-arm study with 261 patients from two participating colorectal units in Austria, indicate that application of Obsidian ASG® at anastomotic site following colorectal resection is safe and associated with a low rate of anastomotic leakage of 2.3% (1). Obsidian ASG® may therefore reduce leakage by more than 50% in gastrointestinal resections.

Gastrointestinal resections often results in anastomotic leakages:
• In Europe more than 450.000 new cases of colorectal cancer every year - most of these will undergo anastomosis surgery
• In up to 19% of gastrointestinal surgeries the resection results in anastomotic leakage making it one of the most dreaded complication following GI surgery
• The cost per patient experiencing anastomotic leakage is up to 4 times higher compared to an uncomplicated procedure

The EIC Accelerator funding allows Vivostat® to conduct a large-scale multicenter clinical trial across the EU (up to15 hospitals in 7 countries) with inclusion of approximately 440 patients. The main objective of the study is to investigate whether the application of Obsidian ASG® during colorectal resection reduce the rate of postoperative anastomotic insufficiency compared to standard anastomotic technique. Market access and reimbursement strategy with focus on Germany, marketing strategy with product launch plans as wells market expansion plans are also key elements in the project. These activities will strengthen and accelerate the commercialization of Obsidian ASG® to the benefit of patients, surgeons, hospitals as well as job creation.

(1) Shamiyeh et al. Obsidian ASG ® Autologous Platelet Rich Fibrin Matrix and Colorectal Anastomotic healing: A Preliminary Study. Surgical Technologies International, Volume 39, 2021.As a result, Obsidian ASG® will save thousands of lives by reducing anastomotic leakages, decrease the immense global healthcare care spending, and generate an accumulated revenue of EUR 53,49 million 5-year post-project for Vivostat.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

Vivostat A/S
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 140 775,00
Address
BORUPVANG 2
3450 Allerod
Denmark

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Danmark Hovedstaden Nordsjælland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 3 058 250,00
My booklet 0 0